Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Proc Natl Acad Sci U S A. 2018 Apr 17;115(16):4223-4227. doi: 10.1073/pnas.1720548115. Epub 2018 Apr 2.

Learned immunosuppressive placebo responses in renal transplant patients.

Author information

1
Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, 45122 Essen, Germany.
2
Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, 45122 Essen, Germany.
3
Clinic of Neurosurgery, University Hospital Essen, University of Duisburg-Essen, 45122 Essen, Germany.
4
Program in Placebo Studies, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA 02215.
5
Department of Infectious Diseases, University Hospital Essen, University of Duisburg-Essen, 45122 Essen, Germany.
6
Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, 45122 Essen, Germany; manfred.schedlowski@uk-essen.de.
7
Department of Clinical Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden.

Abstract

Patients after organ transplantation or with chronic, inflammatory autoimmune diseases require lifelong treatment with immunosuppressive drugs, which have toxic adverse effects. Recent insight into the neurobiology of placebo responses shows that associative conditioning procedures can be employed as placebo-induced dose reduction strategies in an immunopharmacological regimen. However, it is unclear whether learned immune responses can be produced in patient populations already receiving an immunosuppressive regimen. Thus, 30 renal transplant patients underwent a taste-immune conditioning paradigm, in which immunosuppressive drugs (unconditioned stimulus) were paired with a gustatory stimulus [conditioned stimulus (CS)] during the learning phase. During evocation phase, after patients were reexposed to the CS, T cell proliferative capacity was significantly reduced in comparison with the baseline kinetics of T cell functions under routine drug intake (ƞp2 = 0.34). These data demonstrate, proof-of-concept, that learned immunosuppressive placebo responses can be used as a supportive, placebo-based, dose-reduction strategy to improve treatment efficacy in an ongoing immunopharmacological regimen.

KEYWORDS:

T cells; conditioning; immunosuppression; placebo; transplantation

PMID:
29610294
PMCID:
PMC5910853
DOI:
10.1073/pnas.1720548115
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center